Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
DBVT DBV Technologies	$9.58 +0.8%	$9.82	$2.20 ▼ $12.78	$264.31M	-0.36	35,491 shs	21,453 shs
IFRX InflaRx	$1.60 +36.8%	$0.90	$0.71 ▼ $2.82	$107.41M	1.43	577,237 shs	4.12 million shs
JBIO Jade Biosciences	$7.90 -2.2%	$8.58	$6.57 ▼ $105.00	$257.75M	1.04	105,068 shs	47,960 shs
LXEO Lexeo Therapeutics	$4.79 +0.6%	$4.47	$1.45 ▼ $11.96	$258.67M	1.36	289,060 shs	232,724 shs

5G Stocks: The Path Forward is Profitable

Enter your email address and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
DBVT DBV Technologies	0.00%	-4.20%	+6.44%	+23.77%	+112.89%
IFRX InflaRx	0.00%	+75.15%	+86.05%	+97.53%	+0.63%
JBIO Jade Biosciences	0.00%	-4.01%	+14.66%	+789,999,900.00%	+789,999,900.00%
LXEO Lexeo Therapeutics	0.00%	-2.24%	+3.90%	+76.10%	-58.38%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
DBVT DBV Technologies	3.2942 of 5 stars	3.4	5.0	2.5	2.5	0.6
IFRX InflaRx	2.9256 of 5 stars	3.5	4.0	3.8	1.7	0.0
JBIO Jade Biosciences	2.3076 of 5 stars	3.5	0.0	2.6	1.7	0.6
LXEO Lexeo Therapeutics	2.4226 of 5 stars	3.5	1.0	2.9	2.5	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
DBVT DBV Technologies	2.80	Moderate Buy	$14.75	53.97% Upside
IFRX InflaRx	3.00	Buy	$6.60	312.50% Upside
JBIO Jade Biosciences	3.00	Buy	$16.00	102.53% Upside
LXEO Lexeo Therapeutics	3.00	Buy	$15.33	220.11% Upside

Current Analyst Ratings Breakdown

Latest IFRX, LXEO, DBVT, and JBIO Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/15/2025	LXEO Lexeo Therapeutics	Chardan Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$20.00 ➝ $15.00
8/15/2025	LXEO Lexeo Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$15.00 ➝ $9.00
8/14/2025	JBIO Jade Biosciences	Wedbush Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Outperform ➝ Outperform	$17.00 ➝ $18.00
7/31/2025	LXEO Lexeo Therapeutics	Oppenheimer Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Outperform	$20.00
7/14/2025	JBIO Jade Biosciences	Jefferies Financial Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$16.00
6/26/2025	DBVT DBV Technologies	Lifesci Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong-Buy
6/26/2025	DBVT DBV Technologies	JMP Securities Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Market Outperform ➝ Market Outperform	$21.00
6/16/2025	JBIO Jade Biosciences	Guggenheim Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Neutral ➝ Buy	$14.00

(Data available from 9/1/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
DBVT DBV Technologies	$4.15M	63.23	N/A	N/A	$1.42 per share	6.75
IFRX InflaRx	$180K	596.71	N/A	N/A	$1.13 per share	1.42
JBIO Jade Biosciences	N/A	N/A	N/A	N/A	$92.88 per share	N/A
LXEO Lexeo Therapeutics	$650K	397.94	N/A	N/A	$3.53 per share	1.36

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
DBVT DBV Technologies	-$113.92M	-$4.77	N/A	N/A	N/A	-3,220.49%	-287.15%	-138.83%	11/5/2025 (Estimated)
IFRX InflaRx	-$49.85M	-$0.80	N/A	N/A	N/A	N/A	-71.76%	-57.68%	11/14/2025 (Estimated)
JBIO Jade Biosciences	-$69.63M	-$30.33	0.00	∞	N/A	N/A	-51.96%	-47.65%	N/A
LXEO Lexeo Therapeutics	-$98.33M	-$3.26	0.00	N/A	N/A	N/A	-94.65%	-73.36%	11/12/2025 (Estimated)

Latest IFRX, LXEO, DBVT, and JBIO Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/14/2025	Q2 2025	LXEO Lexeo Therapeutics	-$0.64	-$0.60	+$0.04	-$0.60	N/A	N/A
8/13/2025	Q2 2025	JBIO Jade Biosciences	-$0.43	-$0.86	-$0.43	-$0.86	N/A	N/A
8/7/2025	Q2 2025	IFRX InflaRx	-$0.24	-$0.24	N/A	-$0.24	$0.02 million	$0.05 million
7/29/2025	Q2 2025	DBVT DBV Technologies	-$0.21	-$1.55	-$1.34	-$1.55	$0.64 million	$1.74 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
DBVT DBV Technologies	N/A	N/A	N/A	N/A	N/A
IFRX InflaRx	N/A	N/A	N/A	N/A	N/A
JBIO Jade Biosciences	N/A	N/A	N/A	N/A	N/A
LXEO Lexeo Therapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
DBVT DBV Technologies	N/A	2.45	2.45
IFRX InflaRx	N/A	4.10	3.78
JBIO Jade Biosciences	N/A	10.31	10.31
LXEO Lexeo Therapeutics	N/A	4.43	4.43

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
DBVT DBV Technologies	71.74%
IFRX InflaRx	42.39%
JBIO Jade Biosciences	N/A
LXEO Lexeo Therapeutics	60.67%

Insider Ownership

Company	Insider Ownership
DBVT DBV Technologies	1.44%
IFRX InflaRx	16.30%
JBIO Jade Biosciences	24.90%
LXEO Lexeo Therapeutics	5.30%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
DBVT DBV Technologies	80	27.39 million	27.00 million	Optionable
IFRX InflaRx	60	67.13 million	56.19 million	Optionable
JBIO Jade Biosciences	20	32.63 million	24.50 million	N/A
LXEO Lexeo Therapeutics	58	54.00 million	51.14 million	Not Optionable

IFRX, LXEO, DBVT, and JBIO Headlines

Recent News About These Companies

Is Lexeo Therapeutics (NASDAQ:LXEO) In A Good Position To Invest In Growth?

August 29 at 6:42 AM | finance.yahoo.com

Affinity Asset Advisors LLC Acquires Shares of 1,480,881 Lexeo Therapeutics, Inc. $LXEO

August 28, 2025 | marketbeat.com

Lexeo Therapeutics, Inc. (NASDAQ:LXEO) Receives $15.33 Average Target Price from Analysts

August 28, 2025 | americanbankingnews.com

Lexeo Therapeutics, Inc. (NASDAQ:LXEO) Receives Average Recommendation of "Buy" from Analysts

August 27, 2025 | marketbeat.com

What is Chardan Capital's Forecast for LXEO FY2025 Earnings?

August 23, 2025 | marketbeat.com

Insider Selling: Lexeo Therapeutics (NASDAQ:LXEO) CEO Sells 2,735 Shares of Stock

August 21, 2025 | insidertrades.com

Lexeo Therapeutics’ Friedreich Ataxia Gene Therapy Receives FDA Breakthrough Therapy Designation

August 20, 2025 | msn.com

Lexeo Therapeutics (NASDAQ:LXEO) Given New $15.00 Price Target at Chardan Capital

August 17, 2025 | marketbeat.com

Lexeo Therapeutics (NASDAQ:LXEO) Announces Earnings Results

August 17, 2025 | marketbeat.com

Lexeo Therapeutics (NASDAQ:LXEO) Given New $9.00 Price Target at HC Wainwright

August 17, 2025 | marketbeat.com

Lexeo Therapeutics price target lowered to $15 from $20 at Chardan

August 16, 2025 | msn.com

Lexeo Therapeutics reports Q2 EPS (60c) vs (64c) last year

August 14, 2025 | msn.com

Lexeo Therapeutics Appoints New Chief Financial Officer

August 14, 2025 | tipranks.com

Lexeo Therapeutics Reports Second Quarter 2025 Financial Results and Operational Highlights

August 14, 2025 | globenewswire.com

Lexeo Therapeutics (NASDAQ:LXEO) Shares Up 1.8% - What's Next?

August 10, 2025 | marketbeat.com

Lexeo Therapeutics (LXEO) Projected to Post Quarterly Earnings on Monday

August 5, 2025 | marketbeat.com

Lexeo Therapeutics, Inc. (NASDAQ:LXEO) Receives Average Recommendation of "Buy" from Brokerages

August 1, 2025 | marketbeat.com

Lexeo Therapeutics (NASDAQ:LXEO) Coverage Initiated by Analysts at Oppenheimer

August 1, 2025 | marketbeat.com

Oppenheimer Initiates Coverage of Lexeo Therapeutics (LXEO) with Outperform Recommendation

August 1, 2025 | msn.com

Stifel Maintains Buy Rating on Lexeo Therapeutics (LXEO)

July 29, 2025 | msn.com

Lexeo Therapeutics Holds 2025 Annual Stockholders Meeting

July 25, 2025 | theglobeandmail.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

IFRX, LXEO, DBVT, and JBIO Company Descriptions

DBV Technologies NASDAQ:DBVT

$9.58 +0.08 (+0.84%)

Closing price 08/29/2025 03:58 PM Eastern

Extended Trading

$9.58 0.00 (0.00%)

As of 08/29/2025 06:24 PM Eastern

DBV Technologies S.A., a clinical-stage biopharmaceutical company, engages in the research and development of epicutaneous immunotherapy products. Its product pipeline comprising Viaskin Peanut, an immunotherapy product, which has completed Phase 3 clinical trial for the treatment of peanut allergies; and Viaskin Milk which is in Phase 1/2 clinical trial for the treatment of immunoglobulin E (IgE) mediated or cow's milk protein allergy and eosinophilic esophagitis. The company's earlier stage research programs includes vaccine for the respiratory syncytial virus, potential treatments for inflammatory bowel disease, celiac disease, and type I diabetes. In addition, it develops Viaskin technology platform, a platform to potentially treat food allergy. The company has a collaboration with Nestlé Health Science to develop MAG1C, a ready-to-use atopy patch test for the diagnosis of non-IgE mediated CMPA in infants and toddlers. DBV Technologies S.A. was incorporated in 2002 and is headquartered in Montrouge, France.

InflaRx NASDAQ:IFRX

$1.60 +0.43 (+36.75%)

Closing price 08/29/2025 04:00 PM Eastern

Extended Trading

$1.70 +0.10 (+6.25%)

As of 08/29/2025 07:59 PM Eastern

InflaRx N.V., a clinical-stage biopharmaceutical company, discovers and develops inhibitors using C5a technology in Germany and the United States. The company's C5a is an inflammatory mediator that is involved in the progression of a variety of autoimmune and other inflammatory diseases. Its lead product candidate is vilobelimab, a novel intravenously delivered first-in-class anti-C5a monoclonal antibody, which completed the Phase III clinical trial for the treatment of hidradenitis suppurativa, a rare and chronic debilitating systemic inflammatory skin disease; for the treatment of anti-neutrophil cytoplasm antibody associated vasculitis, a rare and life-threatening autoimmune disease that is in Phase II trial; to treat pyoderma gangraenosum, a chronic inflammatory skin disorder that is in Phase IIa exploratory study; and for the treatment of PD-1/PD-L1 inhibitor resistant/refractory locally advanced or metastatic cutaneous squamous cell carcinoma that is in Phase II clinical development stage. The company develops INF904, an oral, small molecule drug candidate for the chronic inflammatory and autoimmune diseases; IFX002 that is in pre-clinical development stage for the treatment of chronic inflammation and autoimmune diseases; and Gohibic (vilobelimab) for the treatment of COVID-19 and broader ARDS. It has co-development agreement with Beijing Defengrei Biotechnology Co. Ltd.; and clinical trial collaboration and supply agreement with Merck & Co. Inc. The company was formerly known as Fireman B.V. and changed its name to InflaRx N.V. in 2017. InflaRx N.V. was founded in 2007 and is headquartered in Jena, Germany.

Jade Biosciences NASDAQ:JBIO

$7.90 -0.18 (-2.23%)

As of 08/29/2025 04:00 PM Eastern

Aerovate Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of drugs that enhance the lives of patients with rare cardiopulmonary diseases in the United States. The company focuses on advancing AV-101, a dry powder inhaled formulation of imatinib for the treatment of pulmonary arterial hypertension, which is in Phase 2b/Phase 3 trial. Aerovate Therapeutics, Inc. was incorporated in 2018 and is headquartered in Waltham, Massachusetts.

Lexeo Therapeutics NASDAQ:LXEO

$4.79 +0.03 (+0.63%)

Closing price 08/29/2025 04:00 PM Eastern

Extended Trading

$4.80 +0.01 (+0.21%)

As of 08/29/2025 06:48 PM Eastern

Lexeo Therapeutics, Inc. operates as a clinical stage genetic medicine company that focuses on hereditary and acquired diseases. The company develops LX2006, which is an AAVrh10-based gene therapy candidate for the treatment of Friedreich's ataxia (FA) cardiomyopathy; LX2020, an AAVrh10-based gene therapy candidate for the treatment of plakophilin-2 arrhythmogenic cardiomyopathy; LX2021, a gene therapy candidate for the treatment of DSP cardiomyopathy associated with it; and LX2022, a gene therapy candidate for the treatment of hypertrophic cardiomyopathy, or HCM caused by TNNI3 gene. It also develops LX1001, an AAVrh10-based gene therapy candidate for the treatment of APOE4 homozygous; LX1020, a gene therapy candidate for the treatment of APOE4 homozygous; LX1021 for the treatment of APOE4 homozygotes; and LX1004 for the treatment of CLN2 Batten disease. The company was incorporated in 2017 and is based in New York, New York.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time